Tacrolimus use in lupus nephritis: A systematic review and meta-analysis

Autoimmunity Reviews

Volumn 15, Issue 1, 2016, Pages 93-101

  Hannah, Jennifer ^a   Casian, Alina ^a   D'Cruz, David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Calcineurin inhibitor; Cyclophosphamide; Lupus nephritis; Proteinuria; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MENSTRUATION DISORDER; META ANALYSIS; PREGNANCY; PREGNANT WOMAN; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; ANIMAL; LUPUS NEPHRITIS;

ANIMALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; PROTEINURIA; REMISSION INDUCTION; TACROLIMUS;

EID: 84955171338     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.09.006     Document Type: Review

References (58)

1. Mok C.C., Tang S.S.K. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 11/15 2004, 117(10):791-795.
2. Bertsias G.K., Tektonidou M., Amoura Z., Aringer M., Bajema I., Berden J.H.M., et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis November 2012, 71(11):1771-1782.
3. Weening J.J., D'AGATI D.V., Schwartz M.M., Seshan S.V., Alpers C.E., Appel G.B., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004, 65(2):521-530.
4. Donadio J.V., Holley K.E., Ferguson R.H., Ilstrup D.M. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978, 299(21):1151-1155.
5. Felson D.T., Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984, 311(24):1528-1533.
6. Bargman J.M. How did cyclophosphamide become the drug of choice for lupus nephritis?. Nephrol Dial Transplant 2009 Feb, 24(2):381-384.
7. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D. Garrido EdR, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46(8):2121-2131.
8. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353(21):2219-2228.
9. The Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324:150-154.
10. Dooley M.A., Jayne D., Ginzler E.M., Isenberg D., Olsen N.J., Wofsy D., et al. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. N Engl J Med 11/17 2011, 365(20):1886-1895. [2015/09].
11. Tamirou F., D'Cruz D., Sangle S., Remy P., Vasconcelos C., Fiehn C., et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis March 10 2015, [Epub ahead of print] http://dx.doi.org/10.1136/annrheumdis-2014-206897.
12. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64(4):1215-1226.
13. (Cited August 10, 2015). https://clinicaltrials.gov/ct2/show/NCT01773616.
14. Mok C.C., Tong K.H., To C.H., Siu Y.P., Au T.C. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005, 68(2):813-817.
15. Andersson J., Nagy S., Groth C.G., Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology Jan 1992, 75(1):136-142.
16. Entani C., Izumino K., Iida H., Fujita M., Asaka M., Takata M., et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron 1993, 64(3):471-475.
17. Takabayashi K., Koike T., Kurasawa K., Matsumura R., Sato T., Tomioka H., et al. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clin Immunol Immunopathol Apr 1989, 51(1):110-117.
18. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. Transplantation proceedings 2005, Elsevier.
19. Yang M., Li M., He W., Wang B., Gu Y. Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis. Exp Ther Med 2014, 7(6):1663-1670.
20. Paez Ardila H.A., Suarez L.E.L., Rodriguez V.A., Quintana G.L. Mycophenolate or tacrolimus compared with cyclophosphamide for the management of lupus nephritis: Systematic review and meta-analysis. Rev Colomb Reumatol Dec 01 2014, 21(4):213-225.
21. Tian S.Y., Feldman B.M., Beyene J., Brown P.E., Uleryk E.M., Silverman E.D. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol 2014 Oct, 41(10):1998-2007.
22. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
23. Wells G., Shea B., O'connell D., Peterson J., Welch V., Losos M., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2000.
24. Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre 2014, [Computer program], The Cochrane Collaboration.
25. Bao H., Liu Z.H., Xie H.L., Hu W.X., Zhang H.T., Li L.S. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol Oct 2008, 19(10):2001-2010.
26. Chen W., Tang X., Liu Q., Chen W., Fu P., Liu F., et al. Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial. Am J Kidney Dis FEB 2011, 57(2):235-244.
27. Hong R., Haijin Y., Xianglin W., Cuilan H., Nan C.A., Hong R., et al. A preliminary study of tacrolimus versus cyclophosphamide in patients with diffuse proliferative lupus nephritis. Nephrol Dial Transplant 2007, 22(Suppl 6):276.
28. Li X., Ren H., Zhang Q., Zhang W., Wu X., Xu Y., et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant Apr 2012, 27(4):1467-1472.
29. Liu Z., Zhang H., Liu Z., Xing C., Fu P., Ni Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med Jan 6 2015, 162(1):18-26.
30. Miyasaka N., Kawai S., Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 2009, 19(6):606-615.
31. Mok C.C., Ying K.Y., Yim C.W., Siu Y.P., Tong K.H., To C.H., et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis Dec 2014, 30.
32. Yap D.Y., Yu X., Chen X.M., Lu F., Chen N., Li X.W., et al. Pilot 24month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology May 2012, 17(4):352-357.
33. Wang S., Li X., Qu L., Wang R., Chen Y., Li Q., et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: A non-randomized prospective cohort study. Lupus August 2012, 21(9):1025-1035.
34. Li L., Zhang H., Shen S., Hu W., Liu Z. Controlled trial of tacrolimus (FK506) vs intravenous cyclophosphamide (IVC) as induction therapy for sever lupus nephritis abstract no: F-PO1006. J Am Soc Nephrol 2005, 16:556A.
35. Alsuwaida A. Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. Mod Rheumatol Feb 2011, 21(1):73-75.
36. Izumi Y., Miyashita T., Migita K. Safety of tacrolimus treatment during pregnancy and lactation in systemic lupus erythematosus: A report of two patients. Tohoku J Exp Med Aug 30 2014, 234(1):51-56.
37. Webster P., Wardle A., Bramham K., Webster L., Nelson-Piercy C., Lightstone L. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 2015, 23(11):1192-1196.
38. Tanaka H., Oki E., Tsugawa K., Nonaka K., Suzuki K., Ito E. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: An open-label pilot study. Lupus 2007, 16(11):896-900.
39. Tanaka H., Oki E., Tsuruga K., Yashiro T., Hanada I., Ito E. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. Clin Nephrol 2009, 72(6):430-436.
40. Tanaka H., Aizawa T., Watanabe S., Oki E., Tsuruga K., Imaizumi T. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus July 2014, 23(8):813-818.
41. Tanaka H., Watanabe S., Aizawa-Yashiro T., Oki E., Kumagai N., Tsuruga K., et al. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: A prospective study in daily clinical practice. Nephron Clin Pract February 2013, 121(3-4):165-173.
42. Patel M., Clarke A.M., Bruce I.N., Symmons D.P. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis Rheum Sep 2006, 54(9):2963-2969.
43. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003, 82(5):299-308.
44. Jakes R.W., Bae S., Louthrenoo W., Mok C., Navarra S.V., Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: Prevalence, incidence, clinical features, and mortality. Arthritis Care Res 2012, 64(2):159-168.
45. Appel G.B., Contreras G., Dooley M.A., Ginzler E.M., Isenberg D., Jayne D., et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol May 2009, 20(5):1103-1112.
46. Liu L., Jiang Y., Wang L., Yao L., Li Z. Efficacy and Safety of Mycophenolate Mofetil versus Cyclophosphamide for Induction Therapy of Lupus Nephritis. Drugs 2012, 72(11):1521-1533.
47. Mak A., Cheak A.A., Tan J.Y., Su H.C., Ho R.C., Lau C.S. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) Aug 2009, 48(8):944-952.
48. Lee Y.H., Song G.G. Relative efficacy and safety of tacrolimus, mycophenolate mofetil and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus 2015, 1-9. [Epub ahead of print].
49. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349(24):2326-2333.
50. Yap D.Y., Yu X., Chen X.M., Lu F., Chen N., Li X.W., et al. Pilot 24month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 2012, 17(4):352-357.
51. Houssiau F.A., Vasconcelos C., D'Cruz D., Sebastiani G.D., de Ramon Garrido E., Danieli M.G., et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis Jan 2010, 69(1):61-64.
52. Szeto C.-, Kwan B.C.-, Lai F.M.-, Tam L.-, Li E.K.-, Chow K.- Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology 2008, 47(11):1678-1681.
53. Textor S.C., Burnett J.C., Romero J.C., Canzanello V.J., Taler S.J., Wiesner R., et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995, 47(5):1426-1433.
54. Faul C., Donnelly M., Merscher-Gomez S., Chang Y.H., Franz S., Delfgaauw J., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008, 14(9):931-938.
55. Chen W., Tang X., Liu Q., Chen W., Fu P., Liu F., et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011, 57(2):235-244.
56. Chen W., Liu Q., Chen W., Tang X., Fu P., Liu F., et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012, 21(9):944-952.
57. Stanhope T.J., White W.M., Moder K.G., Smyth A., Garovic V.D. Obstetric nephrology: lupus and lupus nephritis in pregnancy. Clin J Am Soc Nephrol Dec 2012, 7(12):2089-2099.
58. Ostensen M., Khamashta M., Lockshin M., Parke A., Brucato A., Carp H., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006, 8(3):209.